ASCO 2022 | Stratifying patients with breast cancer by a 7-gene assay for endocrine therapy

Name: Stratifying patients with breast cancer by a 7-gene assay for endocrine therapy
Uploaded: 2022-06-06T00:00:00Z
Duration: 6 min 23 s

Pat W. Whitworth • 6 Jun 2022

ASCO 2022

Breast Cancer

RTOG 9804

Current strategies to identify patients with breast cancer who will benefit from radiotherapy or endocrine therapy have been ineffective, with various trials such as the RTOG 9804 trial (NCT00003857) have failed to elucidate the relevant subgroup of patients. Pat W. Whitworth, MD, Vanderbilt University Medical Center, Nashville, TN, describes the benefit of a 7-gene predictive ductal carcinoma in situ (DCIS) biosignature in discerning patients receiving breast conserving surgery (BCS) for DCIS who will benefit adjuvant endocrine therapy. The assay revealed that patients who had an elevated or residual risk were more likely to benefit from radiotherapy and endocrine therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.